Bilezikian, J.P.
Lin, C.J.F.
Brown, J.P.
Wang, A.T.
Yin, X.
Ebeling, P.R.
Fahrleitner-Pammer, A.
Franek, E.
Gilchrist, N.
Miller, P.D.
Simon, J.A.
Valter, I.
Zerbini, C.A.F.
Libanati, C.
Chines, A.
Funding for this research was provided by:
Amgen
Article History
Received: 20 July 2018
Accepted: 15 May 2019
First Online: 14 June 2019
Compliance with ethical standards
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: JP Bilezikian has received research grants from the National Institutes of Health and has received consulting fees from Amgen, Radius, Ultragenyx, Alexion, and Shire. CJF Lin is a former employee and stockholder of Amgen Inc. JP Brown has received research grants from Amgen Inc., Eli Lilly, and Mereo BioPharma; received consulting fees from Amgen Inc., Eli Lilly, and Merck; and served on the speakers’ bureau for Amgen Inc. and Eli Lilly. AT Wang, X Yin, and A Chines are employees and stockholders of Amgen Inc. P Ebeling has received research grants from Amgen Inc., Eli Lilly, Novartis, and Alexion, and has received consulting fees from Amgen Inc., Eli Lilly, Alexion, and Gilead. A Fahrleitner-Pammer has received consulting fees from Eli Lilly and has served on the speakers’ bureau for Alexion, Amgen Inc., Eli Lilly, and Stada. E Franek has served on the speakers’ bureau for Amgen Inc., Eli Lilly, and MSD. N Gilchrist has received research grants from Amgen Inc. PD Miller has received research grants from Amgen Inc., Alexion, Radius Pharma, and Regeneron. JA Simon has received research grants from AbbVie Inc., Allergan Plc, Agile Therapeutics, Bayer Healthcare LLC., Dornier MedTech, Endoceutics Inc., GTx, Inc., Ipsen, Myovant Sciences, New England Research Institute Inc., ObsEva SA, Palatin Technologies, Symbio Research Inc., TherapeuticsMD, and Tissue Genesis; has ownership in James A. Simon, MD, PC; has received consulting fees from AbbVie Inc., Allergan Plc, AMAG Pharmaceuticals Inc., Amgen Inc., Ascend Therapeutics, Bayer HealthCare Pharmaceuticals Inc., CEEK Enterprises LLC., Covance Inc., Millendo Therapeutics Inc., Mitsubishi Tanabe Pharma Development America Inc., ObsEva SA, Radius Health Inc., Sanofi S.A., Sebela Pharmaceuticals Inc., Shionogi Inc., Symbiotec Pharmalab, TherapeuticsMD, and Valeant Pharmaceuticals; has served on the speakers’ bureau for AMAG Pharmaceuticals Inc., Duchesnay USA, Novo Nordisk, Shionogi Inc., and Valeant Pharmaceuticals; and is a stockholder in Sermonix Pharmaceuticals. I Valter has nothing to disclose. CAF Zerbini has received research grants from Pfizer, Amgen Inc., Sanofi, MSD, Novartis, and Lilly, and has served on the speakers’ bureau for Pfizer, Lilly, and Sanofi. C Libanati is an employee and stockholder of UCB Pharma.